Asthma is a common disease, with a prevalence of approximately 5% to 10% in Western countries. [1] [2] [3] [4] [5] However, there are very few data available on the severity of common asthma, perhaps because of limited consensus in the international community in defining severity. It is well acknowledged that asthma severity has a disproportionate effect on both quality of life and health economics. [6] [7] [8] [9] In the recent European Respiratory Society/ American Thoracic Society guidelines, severe asthma was defined as the inability to achieve or maintain optimal disease control despite use of a combination of high-dose medications and adequately addressing all possible comorbidities. 10 Although these guidelines hypothesized that the prevalence of severe asthma is approximately 5% to 10% of the total asthmatic population, it was acknowledged that the exact prevalence is unknown, again because of the lack of unified definitions and consensus on what exactly constitutes asthma severity. 11 Previous relatively smaller general population studies have suggested that the prevalence of severe asthma ranges from 10% to 24%, although different definitions of severity were applied in these studies. [12] [13] [14] [15] [16] [17] [18] These estimates are imprecise, partly because the definitions are different between clinical and epidemiologic studies. Importantly, a true prevalence of asthma severity can only be calculated from epidemiologic studies of random populations and not from selected hospital-or clinic-based cohorts because of their inherent bias.
The current study reports the prevalence of different signs of asthma severity using a random cohort of patients with active asthma selected from the West Sweden Asthma Study. The data were collected from a postal questionnaire sent to 30,000 random subjects aged 16 to 75 years, with a 62% response rate after controlling for untraceable subjects. 2 To avoid any biased prior definitions of severe asthma, asthma severity phenotypes were identified based on 5 parameters, including lung function, daytime symptoms, nighttime symptoms, use of rescue medications, and asthma exacerbations (oral corticosteroid use, emergency health care visits because of asthma, or both). The relationship between severity phenotypes and the presence of comorbidities was tested, and risk factors were determined.
METHODS

Study population and design
The current study was based on a large-scale population-based study conducted in west Sweden from 2008 to 2012 that has been thoroughly described previously. 2, 15, 19 The study area of west Sweden includes the city of Gothenburg located on the North Sea. Gothenburg is the second largest city in Sweden and had a population of 494,000 at the end of 2007 and a population exceeding 700,000 when including the urbanized areas surrounding the city. The population of the region was 1,547,000 in 2007, which corresponds to approximately one sixth of the Swedish population. A postal questionnaire was sent in February 2008 to 30,000 inhabitants in the region aged 16 to 75 years. A random selection of 15,000 subjects was chosen from the population living in the urbanized area of Gothenburg and its surroundings. Similarly, a random sample of 15,000 subjects of the same age range was chosen from the rest of the region. Names and addresses were acquired from the Swedish Population Register.
We received 18,087 completed questionnaires, for a 62% response rate after correcting for subjects who could not be found or had passed away after acquiring their addresses. Subjects who reported ever having asthma or physician-diagnosed asthma along with a randomly selected group of subjects without asthma were invited to undergo clinical phenotyping, including interviews and multiple physiologic tests. A total of 2,006 individual subjects underwent clinical examinations, which included pulmonary function tests (FEV 1 and forced vital capacity [FVC]) before and after bronchodilation, an inhaled provocation test with methacholine, fraction of exhaled nitric oxide (FENO) measurement, blood sampling, and a skin prick test against a panel of the 11 most common inhalant allergens. Before the examination and blood testing, a detailed clinical interview was also carried out, which included detailed questions about asthma symptoms and use of asthma medications, upper and lower airway comorbidities, triggers or aggravating environmental factors, and socioeconomic status. A detailed flowchart of participant selection, starting with the number of subjects invited initially to the questionnaire survey, is presented as Fig 1. The current analysis focuses primarily on 744 asthmatic patients who showed signs of active asthma, which was defined as ever having asthma or physician-diagnosed asthma and having used asthma medications or having had recurrent wheeze or attacks of shortness of breath with or without wheeze in the last 12 months. For comparisons of age, sex, body mass index (BMI), and smoking status, as well as lung function parameters, FENO values, methacholine reactivity, and skin prick test response positivity, the different groups of asthmatic patients were compared with a control group of subjects considered to have healthy lungs. We included a respiratory healthy reference group consisting of 847 subjects who reported never having had physiciandiagnosed asthma, asthma symptoms, chronic productive cough, use of asthma medications, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, or tuberculosis.
Defining asthma severity
To define asthma severity, we used 5 different asthma parameters aiming to cover a broad spectrum of asthma complaints coupled with a reduction in pulmonary function. Signs of asthma severity included (1) reporting 4 or more daytime asthma symptoms despite the ongoing use of medication (this is a definition of ''multisymptom asthma'' used previously 14 ), (2) impaired lung function corresponding to an FEV 1 of less than 70% of predicted value, (3) daily or almost daily use of rescue medications, (4) nighttime symptoms occurring once or more per week, and (5) lung-related emergency department visits or use of oral steroids regularly or during exacerbations.
The study was approved by the Regional Ethics Review Board in Gothenburg, which has its chancellery at the University of Gothenburg.
Analysis
Statistical analyses on the examined cohort were performed by using IBM SPSS Statistics software for Windows (Version 21.0; IBM, Armonk, NY). From the whole questionnaire data set, less than 1% of data were missing. For other parameters, the following percentages of data were missing: spirometry, 3.8%; FENO, 11.3%; skin prick test, 27.6% (not performed because medications or age >65 years); and methacholine test, 62% (not performed because of low lung function [FEV 1 <70% of predicted value], age >65 years, lack of consent, or tested outside of clinic). Missing data were not included in the analysis. Three subgroups of asthmatic patients were defined, including subjects who presented with 1 of the asthma severity signs, subjects who had 2 or more signs of asthma severity (representing a higher level of severity), and subjects who were considered to have active asthma but did not show any of the asthma severity signs and were regarded as having nonsevere asthma. Comparisons between groups were tested with a x 2 test, and the Mantel-Haenszel test was used for comparing trends when comparing more than 2 groups. Continuous variables were analyzed by using an unpaired t test to compare means between the groups. A P value of less than .05 was regarded as statistically significant.
Univariate analysis was performed as separate binary logistic regression models for each of the factors (age, sex, smoking, obesity, nasal blockage, rhinorrhea, allergic rhinitis, atopy, longstanding cough, morning cough, and sputum production) as an independent variable and severity level as a dependent variable. The reference group for the dependent variable was nonsevere asthma both for asthma with 1 sign of asthma severity and for asthma with 2 or more signs of asthma severity. Consequently, a multinomial logistic regression analysis was performed with the patients with nonsevere asthma as a reference group, including all the variables with significant (P < .05) and borderline significant (P 5.05-.10) association with severity from the unadjusted analysis, including age, smoking status, BMI, nasal blockage, atopy, allergic rhinitis, rhinorrhea, sputum production, and morning and longstanding cough, determining which factors are significantly associated with increased level of severity. The results of these analyses are presented as odds ratios (ORs) and 95% CIs.
RESULTS
Prevalence of severity signs
The prevalence of each sign of asthma severity is presented in Table E1 in this article's Online Repository at www.jacionline. org, and these varied from 8.9% to 13.7% in the active asthma group. The most common sign of severity was multiple daytime symptoms, followed by low FEV 1 and nighttime symptoms.
Description of asthma severity subgroups
We categorized the asthmatic patients into 3 groups according to the severity level of their asthma (Fig 2) . Twenty-three percent of the asthmatic patients expressed only 1 of the 5 severity phenotype characteristics, and 13.2% had 2 or more features of severity. All in all, 36.2% (n 5 269) of the asthmatic patients reported at least 1 sign of asthma severity. Only 5% of the asthmatic patients reported having 3 or more signs of asthma severity (see Table E2 in this article's Online Repository at www.jacionline.org). The third group consisted of the remaining patients with active asthma who did not show any of the described severity signs, and these were designated as having nonsevere asthma.
Because the current study includes data from the random population, we were also able to calculate the prevalence of the severity signs at a population level. Thus from the random population sample of 1172 subjects (Fig 1) , the prevalence of at least 1 severity sign was 3.1%, the prevalence of 2 or more severity signs was 1.3%, and 7.4% had nonsevere asthma.
General characteristics
All 3 groups of asthmatic patients were compared with a reference group (n 5 847) that did not report any signs of lung-related symptoms. The general characteristics of all groups are presented in Table I . Among the 3 asthmatic groups, severity was associated with older age (mean age for > _2 signs was 54.6 6 14.9 years vs 50.9 6 15.1 years for 1 sign and 44.9 6 15.1 years for the nonsevere group, P < .001), but all asthmatic patients combined did not differ in age when compared with the respiratory healthy reference group. Female sex was more prevalent in all 3 asthmatic groups compared with the reference group, but there was no difference among the 3 asthmatic groups. Obesity was significantly associated with greater asthma severity, and the proportions of subjects with BMI greater than 30 kg/m 2 were 40.8%, 29.8%, 20.7%, and 12.8% for the asthmatic patients with 2 or more severity signs, those with 1 severity sign, those with nonsevere asthma, and the respiratory healthy group, respectively (P < .001).
Smoking was reported by 21.5%, 17%, and 9.5% of the asthmatic patients with 2 or more signs of asthma severity, the asthmatic patients with 1 sign, and the patients with nonsevere asthma, respectively (P < .05). Asthmatic patients with 2 or more signs of asthma severity also had more pack years of smoking compared with the other 2 groups of asthmatic patients.
Pulmonary function and clinical characteristics
FVC and the FEV 1 /FVC ratio were significantly lower in the groups with signs of asthma severity compared with the nonsevere asthma group. Bronchial hyperreactivity was present in 88.2% of those with 2 or more signs of asthma severity, but this was not significantly different from the 77.6% and 67.9% seen in those with 1 sign and those with nonsevere asthma, respectively. Importantly, methacholine provocation was not performed in subjects with low lung function (FEV 1 <70% predicted), in those older than 65 years of age, or in those who did not consent to the procedure, and this decreases the statistical power on this parameter. Significantly fewer subjects in the healthy reference group (32%) showed bronchial hyperreactivity (P < .001). FENO values did not differ significantly between the asthmatic groups but was significantly lower in the healthy reference group versus all asthma groups (Table I) .
Regarding allergic status, 61.5% of the patients with nonsevere asthma had positive skin prick test responses, and in this group 48.7% were sensitized to 2 or more aeroallergens. In the group with 1 sign of severity, 46.2% had positive skin prick test responses, and in this group 40.4% were sensitized to 2 or more allergens. Of those with 2 or more signs of asthma severity, 42.9% had at least 1 positive skin prick test response, and in this group 34.7% were sensitized to 2 or more aeroallergens. In the healthy reference group 33.1% were sensitized to at least 1 aeroallergen, and in this group 21.3% were sensitized to 2 or more allergens. Sensitization status did not differ significantly between the different asthmatic groups, but significantly fewer respiratory healthy subjects were sensitized to monoallergens or polyallergens (P < .001).
The mean values of blood eosinophilia differed significantly between the patients with nonsevere asthma and those with 2 or more severity signs (0.23 3 10 9 eosinophils/L vs 0.28 3 10 9 eosinophils/L, respectively, P < .05) but not versus those with 1 sign of severe asthma (0.25 3 10 9 eosinophils/L). The healthy reference group had significantly lower blood eosinophilia (0.18 3 10 9 eosinophils/L, P < .001) than the asthmatic patients, regardless of severity. Inhaled corticosteroids (ICSs) alone or in combination with a long-acting b 2 -agonist were used by 79.6% of the asthmatic patients with 2 or more signs of severity, which was significantly more than in those with nonsevere asthma (53.1%, P < .001) but not significantly more than in the group of asthmatic patients with 1 sign (70.2%, P 5 .09).
The level of asthma control was approximated by the results from the Asthma Control Test (ACT). Only 28.8% of the subjects in the group with 2 or more signs of asthma severity had well-controlled asthma (as indicated by an ACT score >19), whereas in the group with 1 sign, 65.4% had well-controlled asthma, and in the nonsevere group 84.4% had well-controlled asthma (P <.001). Mean ACT scores were 16.9, 20.2, and 22.1 for those with 2 or more signs of asthma severity, those with 1 sign, and those with nonsevere asthma, respectively (P < .001, Fig 3) .
Factors associated with disease severity
Having signs of asthma severity was associated with several factors, as presented in Tables II and III . Older age increased the risk for both asthma severity subgroups in the univariate analysis. Smoking was a significant risk factor for having 1 sign of asthma severity (OR, 2.07; 95% CI, 1.22-3.51) and even more strongly associated with having 2 or more signs of asthma severity (OR, 3.46; 95% CI, 1.85-6.46). The other factors that were associated with asthma severity in the univariate analysis were obesity, longstanding cough, morning cough, and sputum production, whereas nasal blockage was only associated with 2 or more signs J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 6 of asthma severity. Those factors were further included in the multinomial logistic regression by using nonsevere asthma as a reference group. From this analysis, which includes age, smoking, obesity, nasal blockage, sputum production, and longstanding and morning cough, increasing age and sputum production were associated with having 1 sign of asthma severity. Increasing age, longstanding cough, obesity, and sputum production were all associated with having 2 or more signs of asthma severity (Table III) .
We also performed a bivariate analysis not only with those parameters significant at a P value of less than .05 but also with those with borderline significance (P 5 .05-.10). This did not change the results much because for the group with 1 severity sign, atopy and allergic rhinitis were borderline significant variables, and for the group with 2 or more signs of severity, only rhinorrhea was a borderline significant variable. When these were consequently also incorporated into the multinomial logistic regression analysis, the only result that changes is that allergic rhinitis comes up as a significant factor for the group with 1 severity sign (data not shown).
Comorbidities
Asthmatic patients with at least 2 signs of asthma severity reported other pulmonary symptoms and comorbidities more frequently than all other groups (Fig 4) , including cough, nasal obstruction, and COPD, but neither rhinorrhea nor gastroesophageal reflux were associated with asthma severity.
DISCUSSION
The presented data, emerging from a random population study, argue that asthma severity is more common than often suggested, 10 with a prevalence from 13.2% up to 36.2% among those with active asthma, depending on the definition. The indicators of asthma severity used in the current study were selected based on previous studies showing these to be indicative of asthma severity. The lack of unified and categorical definitions on what constitutes asthma severity might indeed make it prone to being underestimated. Our results further show that 13.2% of the asthmatic population has 2 or more signs of asthma severity, and the various combinations of these signs represent a broad array of different phenotypes indicative of asthma severity. In the current study factors associated with asthma severity include age, obesity, and tobacco smoking. Cough was not included in the definition of asthma severity, but it was recognized to be a sign of more severe disease.
Using the definitions of asthma severity phenotypes selected for this study, we report a higher prevalence of asthma severity than any previous publication. 17, [20] [21] [22] We realize that this might be a controversial finding, but it is exceptionally important to note that our data are based on a population study, and there is no bias in patient selection from, for example, clinically selected patient cohorts or Web-based recruitments. Clearly, asthma severity is an exceedingly complex concept to define and to apply in clinical practice, 23 which is why we chose to include multiple phenotypic signs of severity in our calculations. Many patients experience a mixture of complaints, and this can muddle their interpretation even more and make it difficult to determine the severity of the individual patient's illness. However, dissecting the different phenotypes of asthma severity might eventually allow us to deal with the specific problems of an individual asthmatic patient, resulting in more successful personalized asthma management. Because the studied population is randomly selected, it could be speculated that approximately 300,000 Swedish people have some sign of asthma severity because the population of Sweden is 10 million. It is unclear whether these data translate to other countries, such as the United States.
The relevance of epidemiologic data for determining asthma severity could also be criticized because the cohort does not include only patients who are under full and professional asthma management plans. This might be a fair argument, but it should also be considered that Sweden is a country that early and efficiently implemented ICS use, and prescription rates are high. 19 Furthermore, based on epidemiologic data, a higher proportion of asthmatic patients with greater disease severity reported taking ICSs alone or in combination with a long-acting bronchodilator (Table I) . Thus it cannot be concluded from this study that the severity signs reported were due to the lack of adequate treatment in that group overall, except possibly in a limited portion of patients. Furthermore, increasing age is a significant risk factor for having more severe disease, which might reflect structural changes in the lungs over time. 24, 25 Female sex has been reported to be associated with more severe asthma. 7, [26] [27] [28] [29] In this analysis we did not find female sex to be a risk factor for more severe disease, even though women were more represented in all asthma groups. From a mechanistic viewpoint, it is unclear whether sex hormones, 30 perception and behavior trends, 31 or various internal and external factors can explain the often-reported increased severity of asthma in women versus men.
Obesity was significantly associated with more severe asthma, which has also been documented in several previous reports. [32] [33] [34] [35] There are many hypotheses that link obesity to increasing asthma severity, including underlying genetic factors, accompanying comorbidities, or inflammatory mediators secreted by adipose tissue. 36, 37 Indeed, a previous study from the OLIN studies in North Sweden showed that obesity is a risk factor for both allergy-associated and non-allergy-associated asthma. 38, 39 Epidemiologic studies might facilitate the explanation for why severe asthma is more common in obese patients, but bariatric surgery associated with a dramatic weight loss can even eliminate signs of asthma in some subjects. 40 This suggests that a mechanism of asthma in the obese can be simply due to being overweight, whereas in others obesity is a comorbidity that increases severity. 41, 42 Indeed, in some subjects undergoing bariatric surgery, asthma is only improved but not eliminated, suggesting that the subject's obesity influenced the degree of severity but was not the cause of his or her asthma. 43 Thus there might be several underlying mechanisms behind the association between obesity and asthma severity.
We found that tobacco smoking was associated with more severe asthma, and this is in agreement with some previous studies, 44, 45 although some studies have not observed such an association. 46, 47 It is well known that smoking changes the phenotype of asthma, including reducing the therapeutic response to ICSs 48, 49 and reducing the level of nitric oxide in exhaled air. 50 It cannot be excluded that the subjects with a severe asthma , no nasal blockage, no sputum production, no longstanding cough, and no morning cough.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 6 phenotype along with a history of tobacco smoking have varying degrees of COPD-associated pathology in the lung together with asthma and that this contributes to an overlap of COPD and asthma in the same patient.
In our asthma cohort allergic sensitization was not associated with more severe disease, which is an observation that supports several previous studies. 46, 51, 52 By contrast, we observed a negative association between atopy and both levels of asthma severity, and the proportion of nonsensitized subjects was greater in the group with 2 or more signs of asthma severity compared with asthmatic patients with 1 sign of asthma severity or nonsevere asthma. Self-reported allergic rhinitis, as a surrogate estimate of self-reported allergies, was also negatively associated with asthma severity, especially among the group with 2 or more signs of asthma severity. Thus it is possible that nonallergic asthma is in general more closely associated with characteristics of increased asthma severity than allergic asthma.
The most characteristic asthma symptoms, such as wheezing or shortness of breath, were included in the definition of severity signs from the beginning of the analysis, but other complaints, such as longstanding cough and morning cough, as well as sputum production, were studied in relation to other severity signs. Indeed, all of these cough-related problems were significantly more prevalent in the group of asthmatic patients with 2 or more signs of asthma severity. Several other studies have also related the presence of cough to more severe disease with more persistent symptoms despite anti-inflammatory therapy. 53, 54 This observation suggests that cough has a complex presentation in asthma and that it might involve other proinflammatory pathways that are different from the pathophysiologic mechanisms behind the other asthma symptoms that can be treated with conventional asthma therapies. Therefore it is important that these complaints are not taken lightly.
A significant aspect of asthma severity is the extent of medication use and medication adherence. It is complicated to objectively estimate the level of adherence to treatment in epidemiology, partly because of the lack of standardized methods to measure adherence but also because each method has limitations. 55, 56 However, previous data from our cohort 19 and other studies 18, [57] [58] [59] suggest that subjects with more severe disease report greater use of medications, although a subgroup reports that they are not taking any medication on a regular basis. Overall, however, we should assume that the increased level of severity is not likely to depend simply on undertreatment.
One of the drawbacks that epidemiologic studies face is the potential bias of overestimation of disease severity because the patients with more severe asthma might be more prone to participate in studies concerning respiratory morbidity. 60, 61 However, from a validation study on the nonresponders and late responders in this study, 62 symptom estimates were not biased to the study population versus nonrespondents.
Another potential disadvantage of our study could be its cross-sectional design, which only provides a snapshot of the separate severity signs and their degree of overlap without determining the dynamics of disease and aging. However, even though patients might go in and out of the defined ''severity phenotypes'' over time, it is unlikely that the overall prevalence of severity in the population would change.
Lastly, we should note that the term asthma control, which is determined either by the ACT or the ''asthma control questionnaire,'' 63-65 could overlap to some degree of the definition of asthma severity in the current study. For example, the frequent use of a symptom-relieving b 2 -agonist without any other sign of severity, is part of the definition of asthma control.
In conclusion, asthma severity, although challenging to define and evaluate, is far from uncommon. Every third asthmatic patient in our study showed at least 1 sign of asthma severity, and this clearly indicates that there are still many unmet needs in managing this disease. Our study also points out the complexity and overlap of the asthma severity parameters, which indicates Prevalence of symptoms in the patients with nonsevere asthma, patients who report 1 sign of severe asthma, and patients who report 2 or more signs of severe asthma. *P < .05 and ***P < .001. GER, Gastroesophageal reflux; NS, not significant.
that severe asthma is not a uniform type of asthma but consists of a mixture of many different phenotypic variables. Some of the phenotypic indicators of asthma severity are only found together in a small number of patients, whereas other indicators are found in combination in a greater number of patients with severe asthma. Overall, this study illustrates the importance of phenotyping asthmatic patients with signs of more severe disease, which can guide individualized severe asthma management and future clinical study design.
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